Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)
Capitalizing Pablo II: The updated IPO for Royalty Pharma includes a $16.6B market cap and a chart-topping $2.2B raise. Can they beat it?
Pablo Legorreta has sent in his updated S-1 for Royalty Pharma, which predictably sketches out a much bigger picture than the placeholder sent in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
